Tobin Schilke - Jun 30, 2023 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Jun 30, 2023
Transactions value $
-$30,592
Form type
4
Date filed
7/5/2023, 09:11 PM
Previous filing
Jun 5, 2023
Next filing
Aug 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $12K +769 +0.95% $15.61 81.6K Jun 30, 2023 Direct F1
transaction RVNC Common Stock Sale -$42.6K -1.7K -2.08% $25.04 79.9K Jul 3, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.